tiprankstipranks
Advertisement
Advertisement

MRVI Stock Latest News

Maravai’s TrinLink BioTechnologies granted new patent in China
The FlyMaravai’s TrinLink BioTechnologies granted new patent in China
2d ago
MRVI
Maravai Lifesciences announces opening of GMP enzyme manufacturing facility
PremiumThe Fly
Maravai Lifesciences announces opening of GMP enzyme manufacturing facility
1M ago
MRVI
Maravai LifeSciences Refinances Debt, Extends Credit Facilities
PremiumCompany Announcements
Maravai LifeSciences Refinances Debt, Extends Credit Facilities
2M ago
8K
MRVI
Maravai Lifesciences announces refinancing of credit agreement
PremiumThe Fly
Maravai Lifesciences announces refinancing of credit agreement
2M ago
MRVI
Maravai Lifesciences Shareholders Back Board, Pay, Auditor
PremiumCompany Announcements
Maravai Lifesciences Shareholders Back Board, Pay, Auditor
2M ago
8K
MRVI
Maravai Lifesciences Signals Turnaround in Earnings Call
PremiumCompany AnnouncementsMaravai Lifesciences Signals Turnaround in Earnings Call
2M ago
MRVI
Maravai Lifesciences price target raised to $6 from $4.50 at Deutsche Bank
Premium
The Fly
Maravai Lifesciences price target raised to $6 from $4.50 at Deutsche Bank
2M ago
MRVI
Maravai Lifesciences reports Q1 EPS 1c, consensus (5c)
Premium
The Fly
Maravai Lifesciences reports Q1 EPS 1c, consensus (5c)
3M ago
MRVI
Maravai Lifesciences sees FY26 revenue $205M-$215M, consensus $204.9M
PremiumThe Fly
Maravai Lifesciences sees FY26 revenue $205M-$215M, consensus $204.9M
3M ago
MRVI
Maravai Lifesciences Charts Early Turnaround in 2025
PremiumCompany Announcements
Maravai Lifesciences Charts Early Turnaround in 2025
5M ago
MRVI
Maravai Lifesciences price target raised to $3 from $2 at Baird
PremiumThe Fly
Maravai Lifesciences price target raised to $3 from $2 at Baird
5M ago
MRVI
Balanced Risk/Reward Leads to Hold Rating as Restructuring Progress Offsets Ongoing Revenue Pressures
PremiumRatings
Balanced Risk/Reward Leads to Hold Rating as Restructuring Progress Offsets Ongoing Revenue Pressures
5M ago
MRVI
Maravai Lifesciences reports Q4 adjusted EPS (4c), consensus (7c)
PremiumThe FlyMaravai Lifesciences reports Q4 adjusted EPS (4c), consensus (7c)
5M ago
MRVI
Maravai Lifesciences sees FY26 revenue $200M-$210M, consensus $203.26M
Premium
The Fly
Maravai Lifesciences sees FY26 revenue $200M-$210M, consensus $203.26M
5M ago
MRVI
MRVI Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
MRVI Earnings this Week: How Will it Perform?
5M ago
MRVI
Maravai Lifesciences price target raised to $4.50 from $4 at Wells Fargo
PremiumThe Fly
Maravai Lifesciences price target raised to $4.50 from $4 at Wells Fargo
7M ago
MRVI
Maravai Lifesciences director buys $368.5K in common stock
PremiumThe Fly
Maravai Lifesciences director buys $368.5K in common stock
7M ago
MRVI
Closing Bell Movers: Inotiv surges after quarterly results
PremiumThe Fly
Closing Bell Movers: Inotiv surges after quarterly results
8M ago
APYX
AXTA
Maravai Lifesciences CEO buys $702.7K of class A shares
PremiumThe Fly
Maravai Lifesciences CEO buys $702.7K of class A shares
8M ago
MRVI
Maravai LifeSciences Earnings Call: Mixed Signals
PremiumCompany AnnouncementsMaravai LifeSciences Earnings Call: Mixed Signals
9M ago
MRVI
Maravai Lifesciences price target lowered to $4 from $5 at Stifel
Premium
The Fly
Maravai Lifesciences price target lowered to $4 from $5 at Stifel
9M ago
MRVI
Cautious Optimism for Maravai Lifesciences: Hold Rating Amidst Strategic Recovery Efforts
Premium
Ratings
Cautious Optimism for Maravai Lifesciences: Hold Rating Amidst Strategic Recovery Efforts
9M ago
MRVI

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >